Correlation Between Infant Bacterial and XSpray Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Infant Bacterial and XSpray Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Infant Bacterial and XSpray Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Infant Bacterial Therapeutics and XSpray Pharma AB, you can compare the effects of market volatilities on Infant Bacterial and XSpray Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Infant Bacterial with a short position of XSpray Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Infant Bacterial and XSpray Pharma.

Diversification Opportunities for Infant Bacterial and XSpray Pharma

-0.77
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Infant and XSpray is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Infant Bacterial Therapeutics and XSpray Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on XSpray Pharma AB and Infant Bacterial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Infant Bacterial Therapeutics are associated (or correlated) with XSpray Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of XSpray Pharma AB has no effect on the direction of Infant Bacterial i.e., Infant Bacterial and XSpray Pharma go up and down completely randomly.

Pair Corralation between Infant Bacterial and XSpray Pharma

Assuming the 90 days trading horizon Infant Bacterial is expected to generate 3.34 times less return on investment than XSpray Pharma. But when comparing it to its historical volatility, Infant Bacterial Therapeutics is 1.22 times less risky than XSpray Pharma. It trades about 0.05 of its potential returns per unit of risk. XSpray Pharma AB is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  3,800  in XSpray Pharma AB on April 23, 2025 and sell it today you would earn a total of  1,410  from holding XSpray Pharma AB or generate 37.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Infant Bacterial Therapeutics  vs.  XSpray Pharma AB

 Performance 
       Timeline  
Infant Bacterial 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Infant Bacterial Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, Infant Bacterial may actually be approaching a critical reversion point that can send shares even higher in August 2025.
XSpray Pharma AB 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in XSpray Pharma AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, XSpray Pharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Infant Bacterial and XSpray Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Infant Bacterial and XSpray Pharma

The main advantage of trading using opposite Infant Bacterial and XSpray Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Infant Bacterial position performs unexpectedly, XSpray Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XSpray Pharma will offset losses from the drop in XSpray Pharma's long position.
The idea behind Infant Bacterial Therapeutics and XSpray Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments